{"url_path":"/sec/mcrb/8-k/2026-07-08/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-08","source_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-298525-index.html","accession_number":"0001193125-26-298525","cik":"0001609809","ticker":"MCRB","issuer_name":"Seres Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-298525-index.html","primary_entity_key":"0001609809","primary_entity_name":"Seres Therapeutics, Inc."},"word_count":90,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNo.\n\n  \nDescription\n\n10.1\n  \n[Seres Therapeutics, Inc. 2025 Incentive Award Plan (as amended and restated).](d100733dex101.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nSERES THERAPEUTICS, INC.\n\nDate: July 8, 2026\n \n\n \nBy:\n \n\n/s/ Thomas J. DesRosier\n\n \n\n \nName:\n \nThomas J. DesRosier\n\n \n\n \nTitle:\n \nExecutive Vice President and Chief Legal Officer"}